PerkinElmer to buy SIRION Biotech

Reviewed

From RevvityJun 24 2021

PerkinElmer Inc. (PKI) agreed to buy SIRION Biotech GmbH, a provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Headquartered in Munich, Germany, privately held SIRION has about 50 employees based in Germany, the U.S. and France.

The deal will complement PerkinElmer's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bio production and base editing technologies, PerkinElmer said in a statement.

Source:

PerkinElmer Inc.

Posted in: Business / Finance

Tags: B Cell, Cell, CRISPR, Gene, RNAi, T-Cell, Viral Vector

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

APA
Revvity. (2023, August 23). PerkinElmer to buy SIRION Biotech. News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx.
MLA
Revvity. "PerkinElmer to buy SIRION Biotech". News-Medical. 23 November 2024. <https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx>.
Chicago
Revvity. "PerkinElmer to buy SIRION Biotech". News-Medical. https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx. (accessed November 23, 2024).
Harvard
Revvity. 2023. PerkinElmer to buy SIRION Biotech. News-Medical, viewed 23 November 2024, https://www.news-medical.net/news/20210624/PerkinElmer-to-buy-SIRION-Biotech.aspx.